Global Cancer Biomarkers Market 2015-2020 - Market is expected to reach USD 15,973.8 Million

Sep 14, 2015, 10:10 ET from Research and Markets

DUBLIN, Sept. 14, 2015 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/sks639/cancer_biomarkers) has announced the addition of the "Cancer Biomarkers Market by Tumor, Type , Profiling Technology, Application & Geography - Global Forecast to 2020" report to their offering.

The global cancer biomarkers market is expected to reach USD 15,973.8 Million by 2020, at a CAGR of 11.6% from 2015 to 2020

Market growth can be attributed to factors such as rising prevalence of cancer, various technological advancements in omics technologies; increased demand for personalized medicines in cancer therapies; increasing number of clinical trials in developing countries; favorable government research funding for cancer research; and rising R&D expenditures of pharmaceutical companies. However, poorly suited regulatory and reimbursement systems of biomarker tests and high capital investments for biomarker discovery and development are restricting the growth of this market.

In this report, the global cancer biomarkers market is segmented on the basis of type of cancer biomarker, tumor type, profiling technologies, applications, and region. Based on type, the market is segmented into protein biomarkers, genetic biomarkers, and other types of biomarker such as viral, cell, and carbohydrate biomarkers. Based on tumor type, the market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, cervical cancer and other type of cancers include such as gastrointestinal stromal tumors (GIST), lung, ovarian, bladder, pancreatic, kidney, melanoma, and leukemia. Based on profiling technologies, the market is segmented into omics technologies, imaging technologies, immunoassays, cytogenetics, and bioinformatics. Based on applications, the market is segmented into diagnostics, drug discovery and development, prognostics, risk assessment, and others which include surrogate endpoints, recurrence, personalized medicine, and therapeutics. On the basis of regions, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World (Latin America and Middle East and Africa).

The diagnostics segment accounted for a major share of the cancer biomarkers market, followed by drug discovery and development. This is mainly attributed to rising prevalence of cancer; increasing demand for advanced diagnostics tests; increased awareness and acceptance of diagnostics tests; advancement in technologies; and the need for early-stage cancer diagnosis.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Industry Trends

7 By Tumor Type

8 Cancer Biomarkers Market, By Type

9 By Profiling Technologies

10 By Application

11 By Geographic Analysis

12 Competitive Landscape

13 Company Profiles

- Abbott Laboratories
- Affymetrix, Inc.
- Agilent Technologies, Inc.
- Becton, Dickinson and Company
- Hologic, Inc.
- Illumina, Inc.
- Merck & Co. Inc.
- Qiagen N.V.
- Quest Diagnostics Inc.
- Roche Diagnostics Ltd.

For more information visit http://www.researchandmarkets.com/research/sks639/cancer_biomarkers

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

SOURCE Research and Markets



RELATED LINKS

http://www.researchandmarkets.com